



## Chemotherapy-Induced Nausea and Vomiting

### Introduction

#### Product Information

#### ANZEMET® Formulary Kit

#### Patient Assistance and Reimbursement Programs

#### Managed Care

#### Professional Support

#### Sign Up for More Information

#### Anzemet.com Home

For help and inspiration in dealing with nausea and vomiting, tell your patients to...

Go to



## Proven 24-hour control with just one dose



A single-dose regimen the lowest fully off can provide economic and the potential for side effects.

Gralla RJ, et al. ASCO Rec for the use of antiemetic clinical practice guideline 1999;17(9):2971-2994.

The management of chemotherapy-induced nausea and vomiting is a critical aspect of cancer patient care. Antiemetic therapy has become increasingly important to manage the side effects associated with more-aggressive chemotherapy regimens.<sup>2</sup>


The advent of 5-HT<sub>3</sub> receptor antagonists was a significant breakthrough for the practice of oncology. These agents offer greater efficacy and safety than traditional antiemetic therapies, such as metoclopramide.<sup>4,6</sup> Greater control over the vomiting that immediately follows chemotherapy may also help prevent anticipatory nausea and vomiting in subsequent courses of chemotherapy—interrupting a pernicious cycle.<sup>5,7</sup>

### Special features:

- **ANZEMET® CARE Calc**
- **Emetogenic Potential**
- **Patient comfort items**
- **eGreeting tool**
- **Patient education mat**
- **Resources for patient assistance**
- **CARE Rebate**

## IV Optimal control with a single dose

### 24-HOUR EMESIS PREVENTION WITH VARYING DOSES OF CISPLATIN\*



A single dose of ANZEMET® prevents nausea and vomiting in the majority of patients receiving high-dose cisplatin.<sup>1,2,3,4</sup>

\*Results from two separate, multi-center, double-blind, randomized studies. ANZEMET® dose was 1.8 mg/kg. Complete response defined as no emetic episodes and no rescue medication for 24 hours after dosing.

Zofran® is a registered trademark of Glaxo Group Limited.

Kytril® is a registered trademark of Hoffman-La Roche Inc.

ANZEMET® (dolasetron mesylate) specific and selective 5-HT<sub>3</sub> receptor antagonist is available for single-dose intravenous or oral prevention of CINV. The rectal and oral doses of ANZEMET® have been characterized in extensive clinical studies; here for complete dosing information, healthcare providers can prescribe with maximum confidence.

ANZEMET® Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat course: cancer chemotherapy, including high-dose cisplatin.

The most common adverse events (>4%) in chemotherapy patients are headache, fatigue, diarrhea, and bradycardia.

headache, diarrhea, and fever (injection).

ANZEMET® can cause ECG interval changes; it should be administered with caution in patients who have or may develop prolongation of cardiac conduction intervals.

Please see full prescribing information for ANZEMET® Injection and ANZEMET® Tablets.

© 2003 Aventis Pharmaceuticals Inc. This site is intended for use by U.S. residents only.  
[Aventis Pharmaceuticals U.S. Home Page](#) [Terms of Use](#) [Privacy Policy](#)

ANZ-WS-8581-1